Komori
Business alliance4597Solasia Pharma K.K.Medicines

Notice of Additional Investment in SP-05 Development Partner Isofol Medical AB through Exercise of Warrants

The Company has decided to exercise all of its warrants in Isofol Medical AB, equivalent to 2,083,332 shares, and make an additional investment. The additional investment will total SEK 1,979,165.4, while the post-exercise ownership ratio is not disclosed in the body of the notice.

Worth reading
73In focus
Scored from 4 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
1979165.4
SEK (Swedish krona)
Wording
Conditional
How definitive the wording is.

Agreements reached under this partnership

Capital and Business Alliance
4597Solasia Pharma K.K.
Alliance partnerIsofol Medical AB
Details of the alliance
  1. 1

    The Company holds warrants in Isofol Medical AB equivalent to 2,083,332 shares and will exercise all of them.

  2. 2

    The funds will be allocated to part of the SP-05 clinical trial.

  3. 3

    Deepen future collaboration with Isofol Medical AB.

  4. 4

    Benefit from part of the economic value generated by progress in SP-05 development outside Japan.

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

Capital and personnel relationships

This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).

3.25%Our ownership stake in the partner’s shares
Number of shares acquiredEquivalent to 2,083,332 shares; percentage of total shares outstanding: Not disclosed
Acquisition priceSEK 1,979,165.4 (Swedish krona)
Shareholding PolicyThe shares to be acquired will not be subject to a continuing holding lock-up, ensuring a certain degree of liquidity.
About the partner
Business DescriptionLicensor of rights to SP-05 (alholitixorin) / development partner / global original rights holder
LocationSweden
Impact on Business Performance

The Company expects to benefit from part of the economic value generated by progress in SP-05 development. Forward-looking statements do not constitute a commitment to achieve them, and actual results and other factors may vary.

Agreements reached under this partnership
ItemDetails
Name of alliance partnerIsofol Medical AB
Alliance partner's business activitiesLicensor of rights to SP-05 (alholitixorin) / development partner / global original rights holder
Alliance partner's locationSweden
Type of allianceCapital and Business Alliance
Details of the allianceThe Company holds warrants in Isofol Medical AB equivalent to 2,083,332 shares and will exercise all of them., The funds will be allocated to part of the SP-05 clinical trial., Deepen future collaboration with Isofol Medical AB., Benefit from part of the economic value generated by progress in SP-05 development outside Japan.
Number of shares acquiredEquivalent to 2,083,332 shares; percentage of total shares outstanding: Not disclosed
Acquisition priceSEK 1,979,165.4 (Swedish krona)
Shareholding ratio3.25% → Not disclosed
Shareholding PolicyThe shares to be acquired will not be subject to a continuing holding lock-up, ensuring a certain degree of liquidity.
Impact on Business PerformanceThe Company expects to benefit from part of the economic value generated by progress in SP-05 development. Forward-looking statements do not constitute a commitment to achieve them, and actual results and other factors may vary.
Items this document does not state (13)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The shares to be acquired will not be subject to a continuing holding lock-up, ensuring a certain degree of liquidity; the Phase Ib/II clinical trial for SP-05 is progressing smoothly, supporting expectations for further growth in Isofol Medical AB's enterprise value; part of the additional investment will be allocated to the SP-05 clinical trial; and the Company expects to deepen its collaboration with Isofol Medical AB and benefit from part of the economic value generated by progress in SP-05 development outside Japan.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.